m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02684)
Name
cmp5
Synonyms
ChemBridge ID 9033823
    Click to Show/Hide
Status
Investigative
Structure
3D MOL
2D MOL
Formula
C21H22ClN3
InChI
1S/C21H21N3.ClH/c1-2-24-20-9-4-3-8-18(20)19-13-16(10-11-21(19)24)14-22-15-17-7-5-6-12-23-17;/h3-13,22H,2,14-15H2,1H3;1H
InChIKey
LTMOFUKBECEABM-UHFFFAOYSA-N
PubChem CID
6462334
TTD Drug ID
D04NZF
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Protein arginine methyltransferase 5 (PRMT5)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Protein arginine methyltransferase 5 (PRMT5) is a therapeutic target for cmp5. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of cmp5 through regulating the expression of Protein arginine methyltransferase 5 (PRMT5). [1], [2]
References
Ref 1 METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1. J Immunol Res. 2021 Aug 23;2021:6149558. doi: 10.1155/2021/6149558. eCollection 2021.
Ref 2 Clinical pipeline report, company report or official report of Prelude Therapeutics.